Category list : All-Wales Medicines Strategy Group
Sort by: Newest first Oldest first A-Z Z-A
-
Abraxane funded in Wales Subscription
Patients with metastatic pancreatic cancer in Wales will have access to the drug Abraxane (paclitaxel; Celgene) on the NHS following a positive decision from the All Wales Medicines Strategy Group in September 2014. Wales is the only country in the UK where the chemotherapy drug will be routinely available to eligible patients on the NHS.
-
All Wales Medicines Strategy Group Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group: Tocilizumab for juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients aged 2 years and older; Inhaled indacaterol/glycopyrronium as a maintenance bronchodilator in adults with chronic obstructive pulmonary disease; Tenofovir disoproxil film-coated tablets and granules to treat chronic hepatitis B in adults whose disease ...
-
Alogliptin approved for use in Wales Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): alogliptin, in combination with metformin or a sulphonylurea, to treat adults with type 2 diabetes (Vipdomet — a combination tablet containing metformin and alogliptin — is also approved); bortezomib, with dexamethasone, to treat adults with progressive multiple myeloma who have received at least one previous treatment and for whom haematopoietic stem ...
-
Atomoxetine, abatacept, linaclotide and nalmefene recommended for use in Wales
The All-Wales Medicines Strategy Group has endorsed atomoxetine, abatacept, linaclotide and nalmefene for use in NHS Wales in its latest round of medicines appraisals.
-
August 2015: AWMSG approvals Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): brimonidine gel for treating the symptoms of moderate-to-severe, persistent facial erythema associated with rosacea; Rezolsta (darunavir and cobicistat) for use in combination with other antiretroviral medicines to treat human immunodeficiency virus-1 infection in adults; magnesium aspartate dihydrate for treating and preventing magnesium deficiency in patients aged two ...
-
AWMSG decisions Subscription
The following medicines have not been recommended for use by the All Wales Medicines Strategy Group (AWMSG) and should not be prescribed in NHS Wales: Abiraterone (Zytiga) with prednisolone for metastatic castration-resistant prostate cancer in men who are asymptomatic or mildly symptomatic after androgen deprivation therapy (the drug is allowed for patients whose disease has progressed — as per National Institute ...
-
AWMSG decisions Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): eltrombopag to treat thrombocytopenia in adults with hepatitis C infection where the degree of thrombocytopenia is compromising the efficacy of interferon; imatinib for adjuvent treatment of KIT-positive gastrointestinal stromal tumours; Eviplera (emtricitabine, rilpivirine and tenofovir; Gilead) for treatment-experienced adults infected with HIV type 1; and velaglucerase ...
-
AWMSG decisions Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Aripiprazole prolonged release injection as maintenance treatment for schizophrenia in adults stabilised on oral aripiprazole Azithromycin infusion to treat community-acquired pneumonia where parenteral therapy is necessary (however, it should not be used to treat pelvic inflammatory disease) Delta-9-tetrahydrocannabinol (Sativex; GW Pharma) ...
-
AWMSG medicines approvals Subscription
Infliximab biosimilars Inflectra (Hospira) and Remsima (Celltrion) have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG). Both can be used for any licensed indication in accordance with AWMSG or National Institute for Health and Care Excellence guidance and should be prescribed by brand. The group has also approved lurasidone (Latuda; Sunovion) to treat adults with schizophrenia and Anoro Ellipta (umeclidinium and vilanterol; GlaxoSmithKline) to relieve ...
-
AWMSG medicines approvals Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): bedaquiline for pulmonary multidrug‑resistant tuberculosis in adult patients as part of an appropriate combination regimen; daclatasvir for chronic hepatitis C virus infection in adults with significant fibrosis or compensated cirrhosis (as part of combination treatment); defibrotide for severe hepatic veno-occlusive disease alongside haematopoietic stem-cell transplantation ...
Show 10 per page20 per page50 per page
